Format

Send to

Choose Destination
PLoS One. 2012;7(12):e50141. doi: 10.1371/journal.pone.0050141. Epub 2012 Dec 10.

Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific microRNAs.

Author information

1
Comprehensive Cancer Center, The University of Chicago, Chicago, Illinois, United States of America. yLussier@uic.edu

Erratum in

  • PLoS One. 2013;8(6). doi: 10.1371/annotation/2489ae5e-3650-4897-8df6-3e974ca585c4. Gnerlich, Jennifer [corrected to Gnerlich, Jennifer L].

Abstract

RATIONALE:

Strategies to stage and treat cancer rely on a presumption of either localized or widespread metastatic disease. An intermediate state of metastasis termed oligometastasis(es) characterized by limited progression has been proposed. Oligometastases are amenable to treatment by surgical resection or radiotherapy.

METHODS:

We analyzed microRNA expression patterns from lung metastasis samples of patients with ≤ 5 initial metastases resected with curative intent.

RESULTS:

Patients were stratified into subgroups based on their rate of metastatic progression. We prioritized microRNAs between patients with the highest and lowest rates of recurrence. We designated these as high rate of progression (HRP) and low rate of progression (LRP); the latter group included patients with no recurrences. The prioritized microRNAs distinguished HRP from LRP and were associated with rate of metastatic progression and survival in an independent validation dataset.

CONCLUSION:

Oligo- and poly- metastasis are distinct entities at the clinical and molecular level.

PMID:
23251360
PMCID:
PMC3518475
DOI:
10.1371/journal.pone.0050141
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center